Patents by Inventor Judy Bastin

Judy Bastin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules
    Patent number: 6682731
    Abstract: Complexes of SEQ ID NO: 12 and HLA-A2 can be used to generate CTLs. They can be supplemented with IL-6 and IL-12.
    Type: Grant
    Filed: March 23, 2000
    Date of Patent: January 27, 2004
    Assignees: Ludwig Institute for Cancer Research, The Chancellor Masters & Scholars of the University of Oxford, University of Leiden
    Inventors: Alan Townsend, Judy Bastin, Thierry Boon-Falleur, Pierre Van Der Bruggen, Pierre Coulie, Thomas Gajewski, Cornelis J. M. Melief, Marjan J. W. Visseren, Martin W. Kast
  • Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
    Patent number: 5851523
    Abstract: Tumor rejection antigens derived from MAGE tumor rejection precursors have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
    Type: Grant
    Filed: August 15, 1994
    Date of Patent: December 22, 1998
    Assignee: Ludwig Institute for Cancer Research.
    Inventors: Alan Townsend, Judy Bastin, Thierry Boon-Falleur, Pierre van der Bruggen, Pierre Coulie, Thomas Gajewski
  • Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
    Patent number: 5591430
    Abstract: Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
    Type: Grant
    Filed: June 17, 1994
    Date of Patent: January 7, 1997
    Assignees: Ludwig Institute for Cancer Research, The Chancellor, Masters and Scholars of the University of Oxford
    Inventors: Alan Townsend, Judy Bastin, Thierry Boon-Falleur, Pierre van der Bruggen, Pierre Coulie, Thomas Gajewski
  • Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
    Patent number: 5585461
    Abstract: Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
    Type: Grant
    Filed: March 24, 1994
    Date of Patent: December 17, 1996
    Assignees: Ludwig Institute for Cancer Research, The Chancellor, Masters and Scholars of the University of Oxford
    Inventors: Alan Townsend, Judy Bastin, Thierry Boon-Falleur, Pierre van der Bruggen, Pierre Coulie